List view / Grid view
Elevated lipoprotein(a), or Lp(a), is a major risk factor for cardiovascular disease that affects one in five people worldwide, but currently lacks approved therapies. Here, Dr Giles Campion, EVP, Head of R&D and Chief Medical Officer of Silence Therapeutics, describes the company’s approach to developing an investigational siRNA therapy designed…
Blocking a process called trogocytosis could enhance the ability of CAR T-cell therapies to treat cancer, according to research led by University of Pennsylvania scientists. In this Q&A, Dr Serge Fuchs, Elizabeth and William Whitney Clark Professor of Oncology at the University of Pennsylvania School of Veterinary Medicine, US, discusses…
In this article, Bryan Oronsky, Chief Development Officer, and Tony Reid, Chief Executive Officer of EpicentRx, explain how AdAPT-001 uses tumour cells as a factory to make the TGF-beta trap that it carries. This trap neutralises the immunosuppressive protein, transforming growth factor–β to ‘heat up’ tumours and sensitise them to…
In this ebook are articles on immune checkpoint inhibitors and enhancing CAR T-cell therapies.
In this ebook are articles on how artificial intelligence can be used to identify drug candidates, data-lead screening models and autonomous strategies for molecular discovery.
This supplement focuses on how cell and gene therapy can target diseases such as cancer and reduce elevated lipoprotein(a).
A new Drug Target Review issue is now ready to download! This issue features articles which explore how artificial intelligence can enhance screening and ways to find new hits through simultaneous orthogonal screens. Also included are articles on CRISPR, immuno-oncology and RSV vaccines.
This article highlights five of the latest findings revealed using CRISPR that could be used in the development or design of new therapies.
Drug Target Review’s Ria Kakkad recently travelled to Barcelona to attend PEGS Europe’s Protein and Antibody Engineering Summit. In this article, she shares her highlights from the event.
In this article, Drug Target Review’s Ria Kakkad shares some of the most recent progress in discovering a drug for COPD, a disease that remains a major challenge in the medical industry.
In this exclusive Q&A, Dr Robert Baldock, Research Scientist at the University of Portsmouth, discusses the compound hydroquinine and how it could be used as an effective weapon against a pathogen that causes serious infections in humans, mostly hospital patients.
A new study found that as patients age, Huntington’s disease gradually impairs the important cellular housekeeping process autophagy, which is responsible for eliminating waste from cells.
In this Q&A, Dr Stephen Jones from Vilnius University Life Sciences Center discusses his work on the recent developments in genome editing tools at the university.
A new MIT study highlights ailing neurons may activate an inflammatory response from the brain’s microglia immune cells.
Researchers from the University of Illinois at Urbana-Champaign found the evolutionary potential of influenza A virus haemagglutinin is extremely restricted by epistatic interactions with neuraminidase.
